This article is intended for primary care clinicians, cardiologists, pulmonologists, allergist/immunologists, critical care specialists, nurses, pharmacists, public health officials, and other members of the healthcare team caring for patients receiving nonsteroidal anti-inflammatory drugs for acute respiratory infection who may be at increased risk for acute myocardial infarction.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This Enduring Material activity, Medscape Education Clinical Briefs, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 9/1/2016. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Approved for 0.25 AAFP Prescribed credits.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
AAFP Accreditation Questions
Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.
Medscape, LLC designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number 0461-0000-17-040-H01-P).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 3/16/2017
Valid for credit through: 3/16/2018, 11:59 PM EST
processing....
Clinicians commonly prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) for symptom relief in acute respiratory infections (ARIs). However, some previous research suggests that individually, ARI and NSAID use may each increase risk for acute myocardial infarction (AMI).
NSAID use during ARI episodes might act synergistically to compound the risk for AMI, but no previous research has tested this hypothesis. The goal of this nationwide case-crossover study by Wen and colleagues was to evaluate the potential simultaneous effect of ARI and NSAID use on AMI risk using the National Health Insurance Research Database in Taiwan.
Use of NSAIDs during ARIs increases the risk for AMI 3.4-fold if taken by mouth and 7.2-fold with parenteral dosing compared with baseline risk without NSAID use or ARI, according to a report published online February 2 in the Journal of Infectious Diseases.[1]
Experts agree that clinicians should consider patient history and the potential risks before prescribing the drugs to patients with an ARI.
Several studies have shown an increased risk for AMI during an ARI, as well as an increased risk for AMI with NSAID use.
Since 2005, the US Food and Drug Administration has required manufacturers of over-the-counter NSAIDs to include warning labels about elevated risk for cardiac effects; the agency strengthened[2] the warning for MI and stroke in 2015.
However, studies have not previously examined the effect of combined NSAID and ARI exposure.
Therefore, Yao-Chun Wen, MA, from National Taiwan University Hospital, Taipei, and colleagues investigated the possible combined effect of an ARI and NSAID use with a case-crossover study that included 9793 patients with hospitalization for AMI between 2007 and 2011. Using claims data from Taiwan's National Health Insurance Program, the authors compared AMI risk among patients with ARI and NSAID exposure, ARI without NSAID exposure, NSAID exposure only, or no exposure (neither ARI nor NSAID use).
The index date for AMI was the first day of hospitalization, and the case period for AMI extended back 7 days. The matched control period was between 366 and 372 days before the index date. The index date for an ARI was the date of an outpatient visit.
Compared with no exposure, NSAID use during an ARI was associated with a 3.4-fold increased risk for AMI (adjusted odds ratio [aOR], 3.41; 95% confidence interval [CI], 2.80-4.16), ARI without NSAIDs was associated with a 2.7-fold increased risk for AMI (aOR, 2.65; 95% CI, 2.29-3.06), and NSAID use alone was associated with a 1.5-fold increased risk (aOR, 1.47; 95% CI, 1.33-1.62).
Parenteral NSAID delivery in patients with ARI introduced an even greater risk for AMI (aOR, 7.22; 95% CI, 4.07-12.81).
NSAID dosing also made a difference in AMI risk. Low-dose oral NSAIDs to treat ARI symptoms were associated with a 3-fold increased risk for AMI (aOR, 2.95; 95% CI, 2.31-3.75), whereas high-dose oral NSAIDs were associated with a 3.3-fold increased risk for AMI (aOR, 3.32; 95% CI, 2.34-4.93).
"[W]e determined that NSAIDs use during ARI episodes, particularly parenteral NSAIDs use, was associated with a further increased risk of AMI," the researchers conclude.
The "potential joint effect of ARI and NSAIDs" is consistent with increases in cytokine production, accumulation of macrophages in atherosclerotic lesions, and heightened inflammation and coagulation during an ARI, the researchers note. NSAIDs could elevate blood pressure through increased sodium and water retention, which could rupture plaque deposits, and enhance the synthesis of leukotrienes, leading to platelet aggregation, and lower levels of antithrombotic prostaglandin I2.
Charlotte Warren-Gash, PhD, from the London School of Hygiene and Tropical Medicine, London, United Kingdom, and Jacob A. Udell, MD, MPH, from the University of Toronto, Toronto, Ontario, Canada, agree with the researchers that the procoagulation and proinflammatory effects of ARI and NSAIDs may set up a perfect storm of conditions for a cardiac event.
"It is certainly plausible that interaction between these deleterious mechanisms may, in part, explain the greater risk of AMI seen in individuals with ARIs treated with NSAIDs compared with those with untreated ARIs or those with NSAID use alone," they write in an accompanying commentary.[3]
"The report by Wen and colleagues contributes to the evidence for dual effects of AMI triggers and highlights the need for cautious use of NSAIDs in the context of ARI; clinicians should consider both medical conditions and existing medications when prescribing NSAIDs for symptomatic ARI relief," Dr Warren-Gash and Dr Udell conclude.
Limitations of the study include not considering the severity of the ARI (preliminary findings indicate that symptoms that blossom into influenza increase the risk for AMI further), not evaluating individual NSAIDs, and inability to tell whether patients actually took the NSAIDs indicated in their records.
The researchers and commentators have disclosed no relevant financial relationships.
J Infect Dis. Published online February 2, 2017.